Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galectin-9B (LGALS9B) is a predicted protein-coding gene originally annotated as a pseudogene similar to galectin-9, located on human chromosome 17p. It features a typical galectin-like exon-intron structure and sequence similarity to galectin-9, encoding a predicted protein able to bind galactosides. However, functional evidence for LGALS9B as a distinct protein entity in human biology is lacking. It is not currently recognized as a validated molecular target, receptor, or therapeutic entity. Most of the known immunological and biological functions assigned to “galectin-9” in the scientific literature refer to the LGALS9 gene, not LGALS9B. In summary, "Galectin-9B" (LGALS9B) is not a recognized molecular target, receptor, or therapeutic entity. Most available evidence suggests this is either an uncharacterized protein or a pseudogene, with no current functional or disease association established in the literature.
Not applicable—no drugs or therapies documented to act on Galectin-9B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Galectin-9B (LGALS9B).